Episode
Episode 156 - Rafiq Hasan - CEO of Complement Therapeutics
- Podcast
- The BioHub - by Avetix
- Published
- Apr 21, 2026
- Duration seconds
- 1259
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/the-biohub-by-avetix-7252289/episodes/episode-156-rafiq-hasan-ceo-of-complement-therapeutics/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/the-biohub-by-avetix-7252289/episode-156-rafiq-hasan-ceo-of-complement-therapeutics.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
We sit down with Rafiq Hasan, co-founder & CEO of Complement Therapeutics, at their London offices to unpack a milestone-loaded past 6 months. Rafiq shares the company's thesis, based on research from Manchester university, and how in practice they are targeting the complement system. We also dig into a landmark moment for the company - the recent dosing of patients in OPTI-GAIN, their Phase 1/2 clinical trial targeting Geographic Atrophy, a leading cause of irreversible vision loss. Another topic of discussion centers around what it's took to build a biotech from the ground up over the past few challenging years. Definitely worth a listen for anyone building in ophthalmology, gene therapy, or across UK biotech.